![Kristin Abate](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 48 991 $ al 31/08/2026
Kristin Abate is currently Chief Accounting Officer & Executive VP at Karyopharm Therapeutics, Inc., a position held since 2025.
Education includes graduate studies at Boston College and undergraduate studies at Bryant University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/09/2026 | 23.782 ( 0,1 % ) | 48 991 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Comptroller/Controller/Auditor | 01/07/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Boston College
 Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
